gene therapy – Medxy AI

Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A

By MedXY 10/24/2026

Two hemophilia A patients developed persistent high-titer FVIII inhibitors following AAV-mediated gene therapy with a bioengineered FVIII transgene despite prior extensive FVIII exposure.

news Ophthalmology

Advancing Vision: Optogenetic Therapy Offers Hope for Retinitis Pigmentosa Patients

By MedXY 10/12/2026

An open-label trial demonstrates the safety and potential efficacy of ChrimsonR-based optogenetic therapy combined with specialized goggles to enhance light sensitivity in patients with advanced retinitis pigmentosa, offering promising avenues for restoring visual function.

Hematology-Oncology news

One-stage Assay Reveals Enhanced Thrombin Activation by AAV-Derived Factor VIII: Implications for Hemophilia A Gene Therapy

By MedXY 10/09/2026

This study demonstrates that one-stage assay (OSA) factor VIII activity better reflects the functional enhancement of AAV-derived FVIII in hemophilia A gene therapy, offering superior prediction of bleeding phenotype compared to chromogenic substrate assays (CSA).

Hematology-Oncology news

Optimizing Autologous Stem Cell Backup Mobilization with GCSF and Plerixafor in Sickle Cell Disease: Implications for Gene Therapy

By MedXY 09/18/2026

A retrospective study demonstrates the safety and efficacy of GCSF and plerixafor for CD34+ stem cell mobilization as autologous backup in sickle cell patients undergoing alternate donor HSCT, with insights relevant for gene therapy.

Hematology-Oncology news

Sustained Genetic Silencing of BCL11A Using shmiR Vector in Sickle Cell Disease: Long-Term Safety and Efficacy

By MedXY 08/24/2026

This article reviews the first-in-human study demonstrating durable and safe posttranscriptional silencing of BCL11A in sickle cell disease patients using a shmiR vector, resulting in stable fetal hemoglobin induction and clinical benefit over 4+ years.

Cardiology Clinical Updates news

AAVrh.10hFXN Gene Therapy for Friedreich Ataxia Cardiomyopathy: Safety and Preliminary Efficacy in a Nonrandomized Clinical Trial

By MedXY 07/01/2026

This review synthesizes evidence from a pioneering nonrandomized trial demonstrating that intravenous AAVrh.10hFXN gene therapy is safe and may improve cardiac outcomes in Friedreich ataxia cardiomyopathy, highlighting translational advances in precision cardiac gene therapy.

news Ophthalmology

Optimized AAV5-RPGR Gene Therapy Rescues Photoreceptor Integrity and Function in X-Linked Retinitis Pigmentosa Mouse Model

By MedXY 06/13/2026

An optimized AAV5 vector delivering a stabilized human RPGR ORF15 gene significantly restores photoreceptor structure and function in RPGR-deficient mice, demonstrating a promising gene therapy for X-linked retinitis pigmentosa.

Cardiology Internal Medicine news

Cardiomyopathy Gene Therapy Reaches an Inflection Point: From AAV Delivery to Precision Genome Editing

By MedXY 05/12/2026

Gene therapy for cardiomyopathy is moving from concept to clinic, but durable benefit will depend on solving delivery, immunogenicity, cargo, and safety barriers in the failing human heart.

Clinical Updates news

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Clinical Updates Neurology news

Treatment Evolution in 5q-Spinal Muscular Atrophy: Real-World Evidence and Clinical Insights from the SMArtCARE Registry

By MedXY 03/08/2026

This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.

Neurology news Pediatrics

Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial

By MedXY 03/08/2026

The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical development due to a negative benefit-risk profile.

Neurology news Pediatrics

CIFFREO Trial Results: Fordadistrogene Movaparvovec Fails Primary Efficacy Endpoint in Duchenne Muscular Dystrophy

By MedXY 02/24/2026

The Phase 3 CIFFREO trial for the gene therapy fordadistrogene movaparvovec failed to meet its primary efficacy endpoint in boys with Duchenne muscular dystrophy, showing no significant functional improvement over placebo and leading to the discontinuation of its clinical development.

Neurology news Pediatrics

AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis

By MedXY 02/23/2026

A Phase 1-2 trial of AAV9-GLB1 gene therapy in children with Type II GM1 gangliosidosis demonstrates significant biochemical improvements and stabilization of neurodevelopmental decline, marking a pivotal step toward treating this fatal lysosomal storage disorder.

Hematology-Oncology Nephrology news

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

By MedXY 02/22/2026

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Cardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

By MedXY 02/04/2026

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.

Hematology-Oncology news Pediatrics

Beyond the CNS and Skeleton: HSPC-Gene Therapy (OTL-203) Demonstrates Superior Multi-System Efficacy in Hurler Syndrome

By MedXY 01/20/2026

A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for multisystemic lysosomal storage disorders.

Dermatology news Pediatrics

Breaking the Cycle of Chronic Wounds: Prademagene Zamikeracel Sets New Standard for RDEB Treatment

By MedXY 01/07/2026

The Phase 3 VIITAL trial demonstrates that prademagene zamikeracel, an autologous gene-modified cellular sheet, significantly improves healing and reduces pain in patients with recessive dystrophic epidermolysis bullosa (RDEB), offering a transformative approach to managing large, chronic wounds.

Hematology-Oncology Internal Medicine news

Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B

By MedXY 12/19/2025

The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine prophylaxis in the vast majority of participants.

Hematology-Oncology news

Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes

By MedXY 11/11/2025

The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acceptable short‑term safety profile and no genotoxicity detected during follow‑up.

news Otorhinolaryngology Pediatrics

AAV‑OTOF Gene Therapy Restores Substantial Hearing in DFNB9 Across Ages — Rapid, Age‑dependent Benefits in a First-in‑Human Trial

By MedXY 11/04/2025

A single‑arm trial of AAV‑OTOF (Anc80L65) in 10 patients (1.5–23.9 years) with autosomal recessive deafness 9 showed good tolerability and rapid, clinically meaningful hearing gains, with optimal outcomes in children aged 5–8 years; longer follow‑up is required.